J&J Stresses New China Disease Strategy
This article was originally published in PharmAsia News
Executive Summary
Growing by double digits, the world’s largest healthcare company is leveraging its diversified platform and working with the government to tackle highly prevalent local diseases, including lung cancer in the case of China.